Rhythm Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Rhythm Pharmaceuticals is David Meeker, benoemd in Jul2020, heeft een ambtstermijn van 4.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.23M, bestaande uit 9.7% salaris en 90.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde € 9.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 5.4 jaar.

Belangrijke informatie

David Meeker

Algemeen directeur

US$7.2m

Totale compensatie

Percentage CEO-salaris	9.7%
Dienstverband CEO	4.3yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is David Meeker's beloning veranderd ten opzichte van Rhythm Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$262m
Jun 30 2024	n/a	n/a	-US$261m
Mar 31 2024	n/a	n/a	-US$274m
Dec 31 2023	US$7m	US$705k	-US$185m
Sep 30 2023	n/a	n/a	-US$186m
Jun 30 2023	n/a	n/a	-US$182m
Mar 31 2023	n/a	n/a	-US$181m
Dec 31 2022	US$3m	US$652k	-US$181m
Sep 30 2022	n/a	n/a	-US$181m
Jun 30 2022	n/a	n/a	-US$176m
Mar 31 2022	n/a	n/a	-US$166m
Dec 31 2021	US$6m	US$630k	-US$70m
Sep 30 2021	n/a	n/a	-US$62m
Jun 30 2021	n/a	n/a	-US$60m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$15m	US$262k	-US$134m
Sep 30 2020	n/a	n/a	-US$132m
Jun 30 2020	n/a	n/a	-US$134m
Mar 31 2020	n/a	n/a	-US$146m
Dec 31 2019	US$287k	n/a	-US$141m
Sep 30 2019	n/a	n/a	-US$133m
Jun 30 2019	n/a	n/a	-US$115m
Mar 31 2019	n/a	n/a	-US$87m
Dec 31 2018	US$282k	n/a	-US$74m
Sep 30 2018	n/a	n/a	-US$59m
Jun 30 2018	n/a	n/a	-US$53m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$268k	n/a	-US$38m

Compensatie versus markt: De totale vergoeding ($USD 7.23M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.90M ).

Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.

CEO

David Meeker (70 yo)

4.3yrs

Tenure

US$7,230,457

Compensatie

Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Meeker	Chairman	4.3yrs	US$7.23m	0.28% € 9.9m
Hunter Smith	CFO & Treasurer	7.3yrs	US$2.31m	0.16% € 5.6m
Joseph Shulman	Chief Technical Officer	4.3yrs	US$1.74m	0% € 0
Yann Mazabraud	Executive VP & Head of International	4.1yrs	US$1.74m	0.057% € 2.0m
Jennifer Lee	Executive VP & Head of North America	4yrs	US$2.11m	0.0016% € 55.0k
Christopher German	Corporate Controller	1.7yrs	geen gegevens	0.0013% € 44.9k
Alastair Garfield	Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
David Connolly	Head of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Jim Flaherty	Senior VP & General Counsel	4yrs	geen gegevens	geen gegevens
Sarah Ryan	Vice President of Sales & Marketing	no data	geen gegevens	geen gegevens
Pamela Cramer	Chief Human Resources Officer	3.3yrs	geen gegevens	0.022% € 765.4k
Elisabeth Cronert-Bendell	Senior VP & Head of Strategy	2.8yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1RV wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Meeker	Chairman	9yrs	US$7.23m	0.28% € 9.9m
Christopher German	Corporate Controller	1.7yrs	geen gegevens	0.0013% € 44.9k
Jennifer Good	Independent Director	5.4yrs	US$283.77k	0.0049% € 170.0k
David W. McGirr	Independent Director	9yrs	US$308.77k	0.0049% € 170.0k
Edward Mathers	Lead Independent Director	11.7yrs	US$328.77k	0.014% € 497.1k
Lynn Tetrault	Independent Director	3.9yrs	US$298.77k	0.0049% € 170.0k
William Chin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Elizabeth Stoner	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Camilleri	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lee Kaplan	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
John Amatruda	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Stuart Arbuckle	Independent Director	5.3yrs	US$301.27k	0.0049% € 170.0k

5.4yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1RV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Rhythm Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

High number of new directors

Chairman recently bought €172k worth of stock

Recent updates

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology

Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023)

Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024

Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old

Second quarter 2024 earnings released: US$0.55 loss per share (vs US$0.82 loss in 2Q 2023)

Forecast to breakeven in 2026

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome

New minor risk - Profitability

No longer forecast to breakeven

Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

First quarter 2024 earnings released: US$2.35 loss per share (vs US$0.92 loss in 1Q 2023)

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Financial position

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Full year 2023 earnings released: US$3.20 loss per share (vs US$3.48 loss in FY 2022)

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

New minor risk - Profitability

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

New major risk - Share price stability

Forecast to breakeven in 2026

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$0.80 loss in 3Q 2022)

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Second quarter 2023 earnings released: US$0.82 loss per share (vs US$0.89 loss in 2Q 2022)

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022)

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Third quarter 2022 earnings released: US$0.80 loss per share (vs US$0.70 loss in 3Q 2021)

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021)

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment

Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder

High number of new directors

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes

Chief Medical Officer Murray Stewart has left the company